Filing Flows › C4 Therapeutics (CCCC) › Q2 2026
C4 Therapeutics (CCCC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
C4 Therapeutics (CCCC) reported revenue of $6.6M for the second quarter 2026 (Q2 2026), +3% from a year earlier and +8% from the quarter before. Operating margin was -397.9%, net loss $23.6M (355.9% of revenue).
C4 Therapeutics, Q2 2026: revenue $6.6M (+3% year over year), operating margin -397.9%, net loss $23.6M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.6M | +8% | +3% |
| Operating profit | −$26.4M | — | — |
| Net earnings | −$23.6M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $6.6M in Q2 2026, up 3% year over year and up 8% from the previous quarter.
Operating costs exceeded revenue by $26.4M, an operating margin of -397.9%. Total costs fell 5% while revenue rose 3%. The quarter ended with a net loss of $23.6M, narrower than the previous quarter's $25.1M loss.
Operating cash flow was −$1.6M. Non-cash charges added back $292K of depreciation and amortization and $3.0M of share-based compensation. Working capital and other items added $18.7M. Capital expenditures of $37K exceeded it, leaving free cash flow of −$1.6M.
Questions
What was C4 Therapeutics' revenue in the second quarter 2026?
C4 Therapeutics (CCCC) reported revenue of $6.6M for the second quarter 2026 (Q2 2026), +3% from a year earlier and +8% from the quarter before.
Was C4 Therapeutics profitable in the second quarter 2026?
Operating loss was $26.4M (-397.9% of revenue) and net loss $23.6M.
Source: C4 Therapeutics 10-Q on SEC EDGAR.